WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. ((TSX- V:KNE, OTCQB:KNBIF) (the "Company" or "Kane Biotech"), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.
Kane further announces that subsequent to the US $625,000 deposit that it received at the time of the offer, Kane has received additional deposits totaling US $900,000 which will be applied towards the sale price of Kane's interest in STEM.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on ...